Skip to main content



Page 1 of 23

  1. Content type: Letter to the Editor

    We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conj...

    Authors: Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein and Justin Taylor

    Citation: Journal of Hematology & Oncology 2019 12:85

    Published on:

  2. Content type: Review

    Plenty of immune cells infiltrate into the tumor microenvironment (TME) during tumor progression, in which myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cell...

    Authors: Xinyu Tian, Han Shen, Zhiyang Li, Tingting Wang and Shengjun Wang

    Citation: Journal of Hematology & Oncology 2019 12:84

    Published on:

  3. Content type: Correction

    The original article [1] contains an error in Fig. 2 whereby Fig. 2D has mistakenly been omitted. Fig. 2 can be viewed in its entirety – including Fig. 2D – in this Correction article.

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li

    Citation: Journal of Hematology & Oncology 2019 12:83

    Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:56

  4. Content type: Review

    Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improve...

    Authors: Sabarish Ayyappan and Kami Maddocks

    Citation: Journal of Hematology & Oncology 2019 12:82

    Published on:

  5. Content type: Research

    Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance. Altho...

    Authors: Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang and Jichun Zhou

    Citation: Journal of Hematology & Oncology 2019 12:81

    Published on:

  6. Content type: Research

    Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inh...

    Authors: Bhawana George, Suraj Konnath George, Wenyu Shi, Abedul Haque, Ping Shi, Ghazaleh Eskandari, Magnus Axelson, Olle Larsson, Ahmed O. Kaseb and Hesham M. Amin

    Citation: Journal of Hematology & Oncology 2019 12:80

    Published on:

  7. Content type: Research

    The biological function of protein arginine methyltransferase 3 (PRMT3) is not well known because very few physiological substrates of this methyltransferase have been identified to date.

    Authors: Ming-Chuan Hsu, Ya-Li Tsai, Chia-Hsien Lin, Mei-Ren Pan, Yan-Shen Shan, Tsung-Yen Cheng, Skye Hung-Chun Cheng, Li-Tzong Chen and Wen-Chun Hung

    Citation: Journal of Hematology & Oncology 2019 12:79

    Published on:

  8. Content type: Review

    While promising, immunotherapy has yet to be fully unlocked for the preponderance of cancers where conventional chemoradiation reigns. This remains particularly evident in pediatric sarcomas where standard of ...

    Authors: Kyle A. Dyson, Brian D. Stover, Adam Grippin, Hector R. Mendez-Gomez, Joanne Lagmay, Duane A. Mitchell and Elias J. Sayour

    Citation: Journal of Hematology & Oncology 2019 12:78

    Published on:

  9. Content type: Research

    To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates.

    Authors: Tao Jiang, Jinpeng Shi, Zhengwei Dong, Likun Hou, Chao Zhao, Xuefei Li, Beibei Mao, Wei Zhu, Xianchao Guo, Henghui Zhang, Ji He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Chunyan Wu and Caicun Zhou

    Citation: Journal of Hematology & Oncology 2019 12:75

    Published on:

  10. Content type: Review

    During the 1970s, a Na+-independent, ouabain-insensitive, N-ethylmaleimide-stimulated K+-Cl cotransport mechanism was identified in red blood cells for the first time and in a variety of cell types afterward. Du...

    Authors: A. P. Garneau, S. Slimani, L. E. Tremblay, M. J. Fiola, A. A. Marcoux and P. Isenring

    Citation: Journal of Hematology & Oncology 2019 12:74

    Published on:

  11. Content type: Rapid communication

    Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Despite the poor prognosis of DHL, ...

    Authors: Weiping Li, Shiv K. Gupta, Weiguo Han, Ryan A. Kundson, Sara Nelson, Darlene Knutson, Patricia T. Greipp, Sherine F. Elsawa, Eduardo M. Sotomayor and Mamta Gupta

    Citation: Journal of Hematology & Oncology 2019 12:73

    Published on:

  12. Content type: Research

    Acute myeloid leukemia (AML) patients with a high allelic burden of an internal tandem duplication (ITD)-mutated FMS-like Tyrosine Kinase-3 (FLT3) have a dismal outcome. FLT3ITD triggers the proliferation of the ...

    Authors: Maria Solovey, Ying Wang, Christian Michel, Klaus H. Metzeler, Tobias Herold, Joachim R. Göthert, Volker Ellenrieder, Elisabeth Hessmann, Stefan Gattenlöhner, Andreas Neubauer, Dinko Pavlinic, Vladimir Benes, Oliver Rupp and Andreas Burchert

    Citation: Journal of Hematology & Oncology 2019 12:72

    Published on:

  13. Content type: Review

    Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2). In c...

    Authors: Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2019 12:71

    Published on:

  14. Content type: Research

    Glyphosate is the most widely used herbicide in the USA and worldwide. There has been considerable debate about its carcinogenicity. Epidemiological studies suggest that multiple myeloma (MM) and non-Hodgkin l...

    Authors: Lei Wang, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, Zhongxin Lu, Ken H. Young, Xiaodong Ma and Yong Li

    Citation: Journal of Hematology & Oncology 2019 12:70

    Published on:

  15. Content type: Research

    As information on incidence, risk factors, and outcome of acute leukemia (AL) relapse after unmanipulated haploidentical stem cell transplantation (haplo-SCT) is scarce, a retrospective registry study was perf...

    Authors: Simona Piemontese, Ariane Boumendil, Myriam Labopin, Christoph Schmid, Fabio Ciceri, William Arcese, Yener Koc, Zafar Gulbas, Johanna Tischer, Benedetto Bruno, Depei Wu, Didier Blaise, Dietrich Beelen, Giuseppe Irrera, Annalisa Ruggeri, Mohamed Houhou…

    Citation: Journal of Hematology & Oncology 2019 12:68

    Published on:

  16. Content type: Review

    Small cell lung cancer (SCLC) is one of the deadliest cancer types in the world. Despite the high response rate to frontline platinum-containing doublets, relapse is inevitable for the majority of patients and...

    Authors: Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu and Jinming Yu

    Citation: Journal of Hematology & Oncology 2019 12:67

    Published on:

  17. Content type: Research

    The chromosomal rearrangements of the mixed-lineage leukemia gene MLL (KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia. For its oncogenic function, most MLL-fusion proteins ...

    Authors: Krzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, Michael Steckel, Ashley L. Eheim, Andrea Haegebarth and Carlo Stresemann

    Citation: Journal of Hematology & Oncology 2019 12:66

    Published on:

  18. Content type: Research

    Personalized and risk-adapted treatment strategies in multiple myeloma prerequisite feasibility of prospective assessment, reporting of targets, and prediction of survival probability in clinical routine. Our ...

    Authors: Dirk Hose, Susanne Beck, Hans Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jérôme Moreaux and Anja Seckinger

    Citation: Journal of Hematology & Oncology 2019 12:65

    Published on:

  19. Content type: Review

    Inflammation has long been accepted as a key component of carcinogenesis. During inflammation, inflammasomes are potent contributors to the activation of inflammatory cytokines that lead to an inflammatory cas...

    Authors: Shengchao Xu, Xizhe Li, Yuanqi Liu, Yu Xia, Ruimin Chang and Chunfang Zhang

    Citation: Journal of Hematology & Oncology 2019 12:64

    Published on:

  20. Content type: Review

    Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treat...

    Authors: Jianshu Wei, Xiao Han, Jian Bo and Weidong Han

    Citation: Journal of Hematology & Oncology 2019 12:62

    Published on:

  21. Content type: Review

    Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually re...

    Authors: Dwight H. Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone and Kai He

    Citation: Journal of Hematology & Oncology 2019 12:61

    Published on:

  22. Content type: Research

    Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor prognosis, and its treatment remains a challenge due to few targeted medicines and high risk of relapse, metastasi...

    Authors: Qing Xie, Zhijie Yang, Xuanmei Huang, Zikang Zhang, Jiangbin Li, Jianhua Ju, Hua Zhang and Junying Ma

    Citation: Journal of Hematology & Oncology 2019 12:60

    Published on:

  23. Content type: Review

    Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric an...

    Authors: Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan and Xingxing Zang

    Citation: Journal of Hematology & Oncology 2019 12:59

    Published on:

  24. Content type: Review

    Among all malignant tumors that threaten human health, virus-related tumors account for a large proportion. The treatment of these tumors is still an urgent problem to be resolved. The immune system is the “gu...

    Authors: Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma and Peng Wu

    Citation: Journal of Hematology & Oncology 2019 12:58

    Published on:

  25. Content type: Case report

    Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the pote...

    Authors: Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu and Weidong Han

    Citation: Journal of Hematology & Oncology 2019 12:57

    Published on:

  26. Content type: Research

    α3β1 integrin is a promising cancer biomarker and drug target. We previously identified a 9-amino-acid cyclic peptide LXY30 for detecting α3β1 integrin on the surface of live tumor cells. This study was undert...

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li

    Citation: Journal of Hematology & Oncology 2019 12:56

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:83

  27. Content type: Review

    Immunotherapies have led to substantial changes in cancer treatment and have been a persistently popular topic in cancer research because they tremendously improve the efficacy of treatment and survival of ind...

    Authors: Pengfei Zhao, Li Li, Xiaoyue Jiang and Qin Li

    Citation: Journal of Hematology & Oncology 2019 12:54

    Published on:

  28. Content type: Review

    The tumor microenvironment (TME) is an essential intrinsic portion of hepatocellular carcinoma (HCC) for the regulation of its origination, development, invasion, and metastasis. As emerging components of the ...

    Authors: Qin Wu, Lingyun Zhou, Duoduo Lv, Xia Zhu and Hong Tang

    Citation: Journal of Hematology & Oncology 2019 12:53

    Published on:

  29. Content type: Review

    Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cell...

    Authors: Eishiro Mizukoshi and Shuichi Kaneko

    Citation: Journal of Hematology & Oncology 2019 12:52

    Published on:

  30. Content type: Review

    Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic cells in the bone marrow (BM). It is a highly heterogeneous disease, with rising morbidity and mortality in older patient...

    Authors: Yan Liu, Zhiheng Cheng, Yifan Pang, Longzhen Cui, Tingting Qian, Liang Quan, Hongyou Zhao, Jinlong Shi, Xiaoyan Ke and Lin Fu

    Citation: Journal of Hematology & Oncology 2019 12:51

    Published on:

  31. Content type: Research

    Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell...

    Authors: Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Min Wang and Jianxiang Wang

    Citation: Journal of Hematology & Oncology 2019 12:49

    Published on:

  32. Content type: Review

    The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using t...

    Authors: Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho and András Telekes

    Citation: Journal of Hematology & Oncology 2019 12:48

    Published on:

  33. Content type: Review

    Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembroliz...

    Authors: Sen Yang, Zhe Zhang and Qiming Wang

    Citation: Journal of Hematology & Oncology 2019 12:47

    Published on:

  34. Content type: Research

    PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agent...

    Authors: Yuanyuan Yang, Xiaolong Zhang, Fangzhen Lin, Mengshang Xiong, Dongmei Fan, Xiangfei Yuan, Yang Lu, Yuewen Song, Yizi Zhang, Mu Hao, Zhou Ye, Yanjun Zhang, Jianxiang Wang and Dongsheng Xiong

    Citation: Journal of Hematology & Oncology 2019 12:46

    Published on:

  35. Content type: Review

    Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing r...

    Authors: Chao Zhang, Natasha B. Leighl, Yi-Long Wu and Wen-Zhao Zhong

    Citation: Journal of Hematology & Oncology 2019 12:45

    Published on:

  36. Content type: Research

    Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with persistent disease.

    Authors: Francesco Saraceni, Myriam Labopin, Arne Brecht, Nicolaus Kröger, Matthias Eder, Johanna Tischer, Hélène Labussière-Wallet, Hermann Einsele, Dietrich Beelen, Donald Bunjes, Dietger Niederwieser, Tilmann Bochtler, Bipin N. Savani, Mohamad Mohty and Arnon Nagler

    Citation: Journal of Hematology & Oncology 2019 12:44

    Published on:

  37. Content type: Review

    Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for severa...

    Authors: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery and Haitao Zhao

    Citation: Journal of Hematology & Oncology 2019 12:42

    Published on:

  38. Content type: Review

    Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the pas...

    Authors: Hongbing Ma, Iyer Swaminathan Padmanabhan, Simrit Parmar and Yuping Gong

    Citation: Journal of Hematology & Oncology 2019 12:41

    Published on:

  39. Content type: Research

    Successful treatment for acute myeloid leukemia (AML) remains challenging. Inhibiting immune checkpoint to enhance anti-tumor response is an attractive strategy for effective leukemia therapeutics. CD73 is a r...

    Authors: Yaxian Kong, Bei Jia, Chenchen Zhao, David F. Claxton, Arati Sharma, Charyguly Annageldiyev, Joseph S. Fotos, Hui Zeng, Robert F. Paulson, K. Sandeep Prabhu and Hong Zheng

    Citation: Journal of Hematology & Oncology 2019 12:40

    Published on:

  40. Content type: Review

    The Philadelphia (Ph) chromosome, resulting from the t(9;22)(q34;q11) translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of acute lymphoblastic leukemias (ALL). The deregulate...

    Authors: Simona Soverini, Renato Bassan and Thomas Lion

    Citation: Journal of Hematology & Oncology 2019 12:39

    Published on:

  41. Content type: Review

    Breast cancer is the most common malignancy in women all over the world. Genetic background of women contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase t...

    Authors: Zeinab Safarpour Lima, Mostafa Ghadamzadeh, Farzad Tahmasebi Arashloo, Ghazaleh Amjad, Mohammad Reza Ebadi and Ladan Younesi

    Citation: Journal of Hematology & Oncology 2019 12:38

    Published on:

  42. Content type: Research

    Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD73-expressing ...

    Authors: Xiao-Lu Ma, Min-Na Shen, Bo Hu, Bei-Li Wang, Wen-Jing Yang, Li-Hua Lv, Hao Wang, Yan Zhou, An-Li Jin, Yun-Fan Sun, Chuan-Yan Zhang, Shuang-Jian Qiu, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang…

    Citation: Journal of Hematology & Oncology 2019 12:37

    Published on:

  43. Content type: Research

    Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617...

    Authors: Claudia Schubert, Manuel Allhoff, Stefan Tillmann, Tiago Maié, Ivan G. Costa, Daniel B. Lipka, Mirle Schemionek, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, Nicolas Chatain and Steffen Koschmieder

    Citation: Journal of Hematology & Oncology 2019 12:36

    Published on:

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here